Universitätsmedizin Mannheim
Quick facts
Phase 3 pipeline
- Oxaliplatin during radiotherapy · Oncology
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: